1. Alberti G, Zimmet P, Shaw J et al. Type 2 diabetes in the young: the evolving epidemic: the International Diabetes Federation consensus workshop. Diabetes Care 2004; 27: 1798–811.
2. Лазебник Л.Б., Звенигородская Л.А. Метаболический синдром и органы пищеварения. М.: Анахарсис, 2009.
3. Сорвачева Т.Н., Петеркова В.А., Титова Л.Н. и др. Ожирение у подростков. Лечащий врач. 2006; 4: 50–4.
4. Flatt J-P. Importance of nutrient balance in body weight regulation. Diabetes Metab Rev 1988; 6: 571–81.
5. Гинзбург М.М., Козупица Г.С., Крюков Н.Н. Ожирение и метаболический синдром. Влияние на состояние здоровья, профилактика и лечение. Самара: Парус, 2000.
6. Kong AS, Vanderbloemen L, Burge MR. Acanthosis nigricans predicts the clustering of metabolic syndrome components in Hispanic elementary school-aged children. J Pediatr Endocrinol Metab 2012; 25 (11–12): 1095–102.
7. Puri N. А study of pathogenesis of acantosis nigricans and its clinical implications. Indian J Dermatol 2011; 56 (6): 678–83.
8. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008.
9. Алимова И.Л. и др. Под ред. Л.В.Козловой. Метаболический синдром у детей и подростков. М.: ГЭОТАР-Медиа, 2008.
10. Адашева Т.В., Демичева О.Ю. Метаболический синдром – основы патогенетической терапии. Лечащий врач. 2003; 10: 11–7.
11. Ильченко Л.Ю. Фармакокоррекция и немедикаментозные методы лечения у больных с неалкогольным стеатогепатитом. Фарматека. 2007; 12 (146): 50–4.
12. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the obese gene and its human homologue. Nature (London) 1994; 372: 425–32.
13. Flier JS. Leptin expression and action: new experimental paradigms. Proceedings of the National Academy of Sciences USA. 1997; 94: 4242–5.
14. Hassink SG, Sheslow DV, de Lancey E et al. Serum leptin in children with obesity: relationship to gender and development. Pediatrics 1996; 98: 201–3.
15. Mantzoros CS, Varvarigou A, Kaklamani VG et al. Effect of birth weight and maternal smoking on cord blood leptin concentrations of full-term and preterm newborns. J Clin Endocrinol Metab 1997; 82: 2856–61.
16. Casabiell X, Pineiro V, Tome M et al. Presence of leptin in colostrum and/or breast milk from lactating mothers: a potential role in the regulation of neonatal food intake. J Clin Endocrinol Metab 1997; 82: 4270–2.
17. Frisch R, McArther JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science 1974; 185: 949–51.
18. Clement K, Vaiss C, Lahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398–401.
19. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784–92.
20. Lee S, Bacha F, Gungor N, Arslanian SA. Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care 2006; 29: 51–6.
21. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764–69.
22. Yeste D, Carrascosa A. Complicaciones metabólicas de la obesidad infantile. An Pediatr (Barc) 2011.
23. Yeste D, Betancourth S, Gussinyé M et al. Intolerancia a la glucosa en niños y adolescentes obesos. Med Clin (Barc) 2005; 125: 405–8.
24. Диагностика и лечение метаболического синдрома. Рекомендации ВНОК. Кардиоваскулярная терапия и профилактика. 2007; 2 (Прил. 2).
25. Moore RD. Stimulation of Na:H exchange by insulin. Biophys 1981; I (33): 203–10.
26. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Разработаны Комитетом экспертов ВНОК. М., 2004.
27. Захарова И.Н., Звенигородская Л.А., Яблочкова С.В. Метаболический синдром: взгляд педиатра. Эксперим. и клин. гастроэнтерология. 2010; 7: 84–91.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486–97.
29. Малявская С.И., Дворяшина И.В., Терновская В.А. Метаболический инсулинрезистентный синдром: диагностика, клиническое значение, педиатрические аспекты. Монография. Архангельск: Изд-во Северного государственного медицинского университета, 2004.
30. Kinugasa A, Tsunamoto K, Furukawa N et al. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984; 3: 408–14.
31. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48–53.
32. Nadeau K, Klingensmith G, Sokol RJ. Case report: nonalcoholic steatohepatitis in a teenage girl with type 2 diabetes. Curr Opin Pediatr 2003; 15: 127–31.
33. Lavine JE, Schwimmer JB. Non-alcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004; 8: 549–58.
34. Park HS, Han JH, Choi KM, Kim SM. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005; 82: 1046–51.
35. Tominaga K, Kurata JH, Chen YK et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002–9.
36. Метаболический синдром. Под ред. Г.Е.Ройтберг. М.: Медпресс, 2007.
37. Angulo P. Medical progress: nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.
38. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450–5.
39. Богомолов П.О., Павлова Т.В. Неалкогольный стеатогепатит: патофизиология, патоморфология, клиника и подходы к лечению. Фарматека. 2003; 10: 31–9.
40. Duvnjak M, Lerotić I, Barsić N et al. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13 (34): 4539–50.
41. Arkan MC, Hevener AL, Greten FR et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191–8.
42. Захарова И.Н., Звенигородская Л.А., Яблочкова С.В. Метаболический синдром и неалкогольная жировая болезнь печени у детей. Эксперим. и клин. гастроэнтерология. 2011; 11: 44–8.
43. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a “growing” problem? J Hepatol 2007; 46: 1133–42.
44. Schwimmer JB, McGreal N, Deutsch R et al. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005; 115: 561–5.
45. Lobanova YS, Scherbakov AM, Shatskaya VA et al. NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem 2009; 324: 65–71.
46. Xu JW, Gong J, Chang XM et al. Effects of estradiol on liver estrogen receptor-alpha and its mRNA expression in hepatic fibrosis in rats. World J Gastroenterol 2004; 10: 250–4.
47. Schwimmer JB, Celedon MA, Lavine JE et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585–92.
48. Loomba R, Hwang SJ, O’Donnell CJ et al. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008; 134: 953–9.
49. Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641–9.
50. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
51. Schwimmer JB, Deutsch R, Rauch JB et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500–5.
52. Baldridge AD, Perez-Atayde AR, Graeme-Cook F et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127: 700–4.
53. Manton ND, Lipsett J, Moore DJ et al. Non-alcoholic steatohepatitis in children and adolescentееs. Med J Aust 2000; 173: 476–9.
54. Sundaram SS, Zeitler P, Nadeau K et al. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009; 21 (4): 529–35.
55. Nobili V, Vizzutti F, Arena U et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442–8.
56. Roe AH, Dokras A. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Rev Obstet Gynecol 2011; 4 (2): 45–51.
57. Blank SK et al. Polycystic ovary syndrome in adolescence. Ann NY Acad Sci 2008; 1125: 76–84.
58. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181–91.
59. Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metab 1990; 71: 970.
60. Waldstreicher J, Santoro NF, Hall JE et al. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66: 165–72.
61. Venturoli S, Porcu E, Fabbri R et al. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab 1992; 74: 836–41.
62. Caprio S, Plewe G, Diamond MP et al. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 1989; 114: 963–7.
63. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006; 60: 759–63.
64. Nestler JE, Jakubowicz DJ, de Vargas AF et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83: 2001–5.
65. Nestler JE, Powers LP, Matt DW et al. A direct effect of hyperinsulinemia on serum sex hormonebinding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83–9.
66. Venturoli S, Porcu E, Fabbri R et al. Menstrual irregularities in adolescents: hormonal pattern and ovarian morphology. Horm Res 1986; 24: 269.
67. Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril 2006; 86 (Suppl. 1): 6.
68. Rosenfield RL et al. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Ped Endo Metab 2000; 13: 1285–9.
69. Hart R. Polycystic ovarian syndrome – prognosis and treatment outcomes. Curr Opin Obstet Gynecol 2007; 19: 529–35.
70. Van Hooff, Voorhorst FJ, Kaptein MB et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod 2004; 19: 383–92.
71. Tsouli SG, Liberopoulos EN, Mikhailidis DP et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293–301.
72. Pacifico L, Cantisani V, Anania C et al. Serum uric acid and its relation with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol 2009; 160: 45–52.
73. Oyama C, Takahashi T, Oyamada M et al. Serum uric acid as an obesity-related indicator in early adolescence. Tohoku J Exp Med 2006; 209: 257–62.
74. Liu CS, Li TC, Lin CC. The epidemiology of hyperuricemia in children of Taiwan aborigines. J Rheumatol 2003; 30: 841–5.

И.Н.Захарова1, Л.А.Звенигородская2, С.И.Малявская3, Т.М.Творогова1, С.В.Яблочкова1

1 ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России;
2 ГБУЗ Центральный научно-исследовательский институт гастроэнтерологии Департамента здравоохранения г. Москвы;
3 ГБОУ ВПО Северный государственный медицинский университет Минздрава России